Accordingly, it is not surprising that a leading institution such as Johns Hopkins Medicine is at the forefront of this trend. John Hopkins University was an early participant in the clinical ...
— Clinical evidence continues to highlight TULSA’s ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH — TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Profound ...
Profound Medical ( ($TSE:PRN) ) has shared an announcement. Profound Medical announced that The Johns Hopkins Hospital has performed its first ...
Profound Medical Celebrates The Hong Center’s 200th Independent TULSA Procedure for Prostate Disease
TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...
TORONTO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...
New BPH module and clinical data reinforce the TULSA Procedure™’s versatility in prostate disease, superior patient benefits, and potential for mainstream adoption TORONTO, Nov. 28, 2025 (GLOBE ...
TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable ...
SSM Health Saint Louis University Hospital recently performed the first transurethral ultrasound ablation (TULSA) procedure in Missouri as well as the larger Midwest region. It’s a minimally invasive ...
Traditional surgical and radiological approaches – along with a growing number of emerging technologies – to prostate cancer have made it a controllable disease for many men. At the same time, the ...
Credit: Thinkstock By 5 years, 92% of men recovered pad-free continence, and 87% had preserved erectile function sufficient for penetration. MRI-guided whole-gland transurethral ultrasound ablation ...
— Clinical evidence continues to highlight TULSA’s ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH — “The various presentations made at AUA and other major ...
— So far this year alone, 25 TULSA-related scientific research presentations have been delivered at major medical meetings around the world — — Of those, eight (8) presentations were from leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results